vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and Simpson Manufacturing Co., Inc. (SSD). Click either name above to swap in a different company.
Simpson Manufacturing Co., Inc. is the larger business by last-quarter revenue ($588.0M vs $360.9M, roughly 1.6× LivaNova PLC). Simpson Manufacturing Co., Inc. runs the higher net margin — 15.0% vs 8.6%, a 6.4% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs 9.1%). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -0.8%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Simpson Manufacturing Company is a leading building materials manufacturer in the United States that produces structural connectors, fasteners, anchors, and products for new construction and retrofitting.
LIVN vs SSD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $588.0M |
| Net Profit | $30.9M | $88.2M |
| Gross Margin | 65.2% | 45.2% |
| Operating Margin | 11.8% | 19.5% |
| Net Margin | 8.6% | 15.0% |
| Revenue YoY | 12.1% | 9.1% |
| Net Profit YoY | -44.7% | 13.3% |
| EPS (diluted) | $0.57 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $588.0M | ||
| Q4 25 | $360.9M | $539.3M | ||
| Q3 25 | $357.8M | $623.5M | ||
| Q2 25 | $352.5M | $631.1M | ||
| Q1 25 | $316.9M | $538.9M | ||
| Q4 24 | $321.8M | $517.4M | ||
| Q3 24 | $318.1M | $587.2M | ||
| Q2 24 | $318.6M | $597.0M |
| Q1 26 | — | $88.2M | ||
| Q4 25 | $30.9M | $56.2M | ||
| Q3 25 | $26.8M | $107.4M | ||
| Q2 25 | $27.2M | $103.5M | ||
| Q1 25 | $-327.3M | $77.9M | ||
| Q4 24 | $55.9M | $55.4M | ||
| Q3 24 | $33.0M | $93.5M | ||
| Q2 24 | $16.3M | $97.8M |
| Q1 26 | — | 45.2% | ||
| Q4 25 | 65.2% | 43.4% | ||
| Q3 25 | 68.4% | 46.4% | ||
| Q2 25 | 67.8% | 46.7% | ||
| Q1 25 | 69.7% | 46.8% | ||
| Q4 24 | 68.2% | 44.0% | ||
| Q3 24 | 70.8% | 46.8% | ||
| Q2 24 | 68.7% | 46.7% |
| Q1 26 | — | 19.5% | ||
| Q4 25 | 11.8% | 13.9% | ||
| Q3 25 | 15.1% | 22.6% | ||
| Q2 25 | 15.4% | 22.2% | ||
| Q1 25 | 15.3% | 19.0% | ||
| Q4 24 | 11.5% | 14.8% | ||
| Q3 24 | 11.2% | 21.3% | ||
| Q2 24 | 12.6% | 22.1% |
| Q1 26 | — | 15.0% | ||
| Q4 25 | 8.6% | 10.4% | ||
| Q3 25 | 7.5% | 17.2% | ||
| Q2 25 | 7.7% | 16.4% | ||
| Q1 25 | -103.3% | 14.5% | ||
| Q4 24 | 17.4% | 10.7% | ||
| Q3 24 | 10.4% | 15.9% | ||
| Q2 24 | 5.1% | 16.4% |
| Q1 26 | — | $2.13 | ||
| Q4 25 | $0.57 | $1.34 | ||
| Q3 25 | $0.49 | $2.58 | ||
| Q2 25 | $0.50 | $2.47 | ||
| Q1 25 | $-6.01 | $1.85 | ||
| Q4 24 | $1.04 | $1.31 | ||
| Q3 24 | $0.60 | $2.21 | ||
| Q2 24 | $0.30 | $2.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $341.0M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $2.1B |
| Total Assets | $2.6B | $3.0B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $341.0M | ||
| Q4 25 | $635.6M | $384.1M | ||
| Q3 25 | $646.1M | $297.3M | ||
| Q2 25 | $593.6M | $190.4M | ||
| Q1 25 | $738.4M | $150.3M | ||
| Q4 24 | $428.9M | $239.4M | ||
| Q3 24 | $346.4M | $339.4M | ||
| Q2 24 | $329.2M | $354.9M |
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | $300.0M | ||
| Q3 25 | $434.5M | $371.3M | ||
| Q2 25 | $430.6M | $376.9M | ||
| Q1 25 | $628.2M | $382.5M | ||
| Q4 24 | $627.0M | $388.1M | ||
| Q3 24 | $625.5M | $393.8M | ||
| Q2 24 | $624.5M | $399.4M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.2B | $2.0B | ||
| Q3 25 | $1.2B | $2.0B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $1.9B | ||
| Q2 24 | $1.2B | $1.8B |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $2.6B | $3.1B | ||
| Q3 25 | $2.6B | $3.0B | ||
| Q2 25 | $2.5B | $3.0B | ||
| Q1 25 | $2.6B | $2.8B | ||
| Q4 24 | $2.5B | $2.7B | ||
| Q3 24 | $2.5B | $2.9B | ||
| Q2 24 | $2.5B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | 0.15× | ||
| Q3 25 | 0.38× | 0.19× | ||
| Q2 25 | 0.38× | 0.20× | ||
| Q1 25 | 0.61× | 0.21× | ||
| Q4 24 | 0.47× | 0.21× | ||
| Q3 24 | 0.48× | 0.21× | ||
| Q2 24 | 0.50× | 0.23× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | — |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $82.4M | $155.7M | ||
| Q3 25 | $85.1M | $170.2M | ||
| Q2 25 | $62.9M | $125.2M | ||
| Q1 25 | $24.0M | $7.6M | ||
| Q4 24 | $78.7M | $115.8M | ||
| Q3 24 | $51.0M | $103.3M | ||
| Q2 24 | $43.4M | $111.1M |
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $119.0M | ||
| Q3 25 | $62.2M | $133.9M | ||
| Q2 25 | $47.8M | $87.3M | ||
| Q1 25 | $13.2M | $-42.6M | ||
| Q4 24 | $68.3M | $60.3M | ||
| Q3 24 | $32.8M | $58.1M | ||
| Q2 24 | $31.2M | $70.9M |
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | 22.1% | ||
| Q3 25 | 17.4% | 21.5% | ||
| Q2 25 | 13.6% | 13.8% | ||
| Q1 25 | 4.2% | -7.9% | ||
| Q4 24 | 21.2% | 11.7% | ||
| Q3 24 | 10.3% | 9.9% | ||
| Q2 24 | 9.8% | 11.9% |
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | 6.8% | ||
| Q3 25 | 6.4% | 5.8% | ||
| Q2 25 | 4.3% | 6.0% | ||
| Q1 25 | 3.4% | 9.3% | ||
| Q4 24 | 3.2% | 10.7% | ||
| Q3 24 | 5.7% | 7.7% | ||
| Q2 24 | 3.8% | 6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.67× | 2.77× | ||
| Q3 25 | 3.18× | 1.58× | ||
| Q2 25 | 2.32× | 1.21× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | 1.41× | 2.09× | ||
| Q3 24 | 1.55× | 1.10× | ||
| Q2 24 | 2.65× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
SSD
Segment breakdown not available.
